Validation of HPLC and TLC analytical methods to determine radiochemical purity of 99mTc-cAbVCAM1-5, a new experimental radiotracer.

[1]  M. Shapiro,et al.  There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness , 2022, American journal of preventive cardiology.

[2]  G. Baldari,et al.  Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [68Ga]Ga-NODAGA-Exendin-4 Produced by a Fully Automated Method , 2022, Molecules.

[3]  K. Kopka,et al.  Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer , 2021, Pharmaceuticals.

[4]  S. G. Elci,et al.  Validation of HPLC method for the determination of chemical andradiochemical purity of a 68Ga-labelled EuK-Sub-kf-(3-iodo-y-) DOTAGA , 2021, Turkish journal of chemistry.

[5]  M. Ocak,et al.  Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals , 2021, EJNMMI Radiopharmacy and Chemistry.

[6]  C. Decristoforo,et al.  Development and validation of the HPLC method for quality control of radiolabelled DOTA-TATE and DOTA-TOC preparations. , 2020, Nuclear medicine and biology.

[7]  G. Baldari,et al.  A Rapid and Specific HPLC Method to Determine Chemical and Radiochemical Purity of [68Ga] Ga-DOTA-Pentixafor (PET) Tracer: Development and Validation. , 2020, Current radiopharmaceuticals.

[8]  Nic Gillings,et al.  EANM guideline on the validation of analytical methods for radiopharmaceuticals , 2020, EJNMMI Radiopharmacy and Chemistry.

[9]  A. Hafiane.  Vulnerable Plaque, Characteristics, Detection, and Potential Therapies , 2019, Journal of cardiovascular development and disease.

[10]  Lingzhou Zhao,et al.  Early Phase I Study of a 99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer , 2019, The Journal of Nuclear Medicine.

[11]  Erik de Blois,et al.  Radiochemical and analytical aspects of inter-institutional quality control measurements on radiopharmaceuticals , 2019, EJNMMI Radiopharmacy and Chemistry.

[12]  D. Boturyn,et al.  In Vivo Molecular Imaging of Atherosclerotic Lesions in ApoE−/− Mice Using VCAM-1–Specific, 99mTc-Labeled Peptidic Sequences , 2013, The Journal of Nuclear Medicine.

[13]  S. Nissen.  The vulnerable plaque "hypothesis": promise, but little progress. , 2009, JACC. Cardiovascular imaging.